investors shouldn't sell despite the huge price move today
this is just the beginning - the company just addressed all of the legacy investor concerns with the company and additionally accelerated the path to profitability with the in-licensing of an already established new drug for the US market. Institutional investors will line up to buy shares going forward - this might easily reach $10 until the end of the year.
In reading the details, I agree, seems HZNP cleaned up question areas, wiped the slate clean, got favorable terms, and a nice new product to boot. Using sports terminology,t his deal could make HZNP a title contender over night.